Finance Watch: Poseida, Nkarta And Inventiva Are July’s First Biopharma IPOs
Executive Summary
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
You may also be interested in...
GSK Venture Capital Arm Goes Independent With $500m Fund
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.
Vir/GSK Move Lead Coronavirus Antibody Into Phase III
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
Need a specific report? 1000+ reports available
Buy Reports